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1. Introduction 
1.1. The immune system 
 
The immune system refers to a collection of cells and proteins that function to protect our 
body from foreign antigens. It simplistically consists of two “lines of defense”: innate 
immunity and adaptive immunity (1–3).  
Innate immunity is the first line of defense to pathogen. It is an antigen-independent (non-
specific) defense mechanism that is used by the host directly or within hours of encountering 
an antigen. 
The main function of innate immunity is the recruitment of immune cells to sites of infection 
and inflammation through the production of cytokines (small proteins involved in cell-cell 
communication), leading to the release of antibodies and other proteins and glycoproteins 
which activate the complement system. It can also activate the adaptive immune response 
through a process well-known as antigen presentation (2). 
Adaptive immunity matures when innate immunity is ineffective in eliminating infectious 
agents. Adaptive immunity is antigen-dependent and antigen-specific, therefore includes a lag 
time between exposure to the antigen and maximal answer. The main functions of the 
adaptive immune response are the recognition of specific “non-self” antigens in the presence 
of “self” antigens, the generation of pathogen-specific immunologic effector pathways that 
eliminate specific pathogens or pathogen infected cells and the development of an 
immunologic memory. The cells of the adaptive immune system include: T cells, which are 
activated through the action of antigen presenting cells (APCs) and B cells (3) (4). 
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1.2.  T- lymphocytes 
 
Lymphocytes also arise in the bone marrow. In contrast to B cells, which mature within the 
bone marrow, T cells migrate to the thymus gland to develop. During its maturation within 
the thymus, the T cell comes to express a unique antigen-binding molecule called the T-cell 
receptor (TCR). TCR can recognize only antigen that is bound to cell-membrane proteins 
called major histocompatibility complex (MHC) molecules. There are two major types of 
MHC molecules: class I MHC molecules, which are expressed by closely all nucleated cells,  
class II MHC molecules, which are expressed only by antigen-presenting cells (4). 
There are two well-distinct subpopulations of T cells: T helper (TH) and T cytotoxic (TC) 
cells which can be distinguished from one another by the presence of either CD4 or CD8 
membrane glycoproteins on their surfaces, respectively (4).  
After a TH cell recognizes and interacts with an antigen– MHC class II molecule complex, 
the cell is activated and secretes several cytokines which play a central role in activating B 
cells, TC cells, macrophages and various other cells, that contribute in the immune answer. 
Differences in the pattern of cytokines produced by activated TH cells result in different types 
of immune response (4). 
Under the influence of TH-derived cytokines, a TC cell that recognizes an antigen–MHC 
class I molecule complex proliferates and differentiates into an effector cell called a cytotoxic 
T lymphocyte (CTL). CTL generally does not secrete many cytokines and instead exhibits 
cell-killing or cytotoxic activity. The CTL has a vital function in monitoring the cells of the 
body and eliminating any cell that displays antigen such as virus-infected cells, tumor cells 
and cells of a foreign tissue graft. Cells that show foreign antigen complexed with a class I 
MHC molecules are called altered self-cells; these are targets of CTLs (4). 
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1.3.  T cell activation and proliferation  
 
Once it has been bound by MHC α and β molecules, the antigenic peptide is presented to the 
specific T cell which first forms a bond with α and β chains to form tri-molecular complex. 
The bond is stabilized by the CD4/CD8 molecules. Following engagement, three transcription 
factors namely nuclear factor of activated T cells (NFAT), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) will be activated (5, 6). 
The interaction between these molecules leads to the synthesis of important cytokines such as 
Interleukin -2 (IL-2) and Interferon gamma (IFN-γ) as well as the up-regulation of Janus 
kinase 3 (Jak3) expression (Figure 1) (6–9). TCR stimulated production of IL-2 and other 
cytokines starts the cascade of signaling events, leading to the activation of Jak3 which in turn 
phosphorylates signal transducer and activator of transcription 5 (STAT5) (Figure 1) (9). 
Phosphorylated STAT5 (pSTAT5) translocate into the nucleus to regulate transcription of the 
target genes including the IL-2 receptor α (IL-2Rα) (CD25) (Figure 1) (10–12), a prerequisite 
for the formation of the high affinity IL-2Rαβγ (10, 13, 14). The induction of the functional 
system composed of IL-2 and the high affinity IL-2R is critical for G1 progression and for 
mounting an effective immune response (Figure 1) (10, 15). 
 
Figure 1. Schematic presentation of the signal cascade following T cell receptor stimulation (16). 
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1.4. JAK-STATs signaling pathways 
 
Cytokines are proteins that are secreted and intermediate communication between cells. 
Several, if not most, cytokines use the Jaks-STATs signaling pathways to mediate gene 
activation or repression (17). 
Jaks are protein tyrosine kinases that are pre-associated with membrane-proximal regions 
(termed box 1 and box 2) of cytokine receptors. It appears that only four mammalian Jaks 
exist: Jak1, Jak2, Jak3, and Tyk2. Each has a catalytically active kinase domain and a 
regulatory pseudo kinase domain at the carboxy terminus of the protein (17). The domain 
responsible for the binding of Jaks to receptors is located at the amino terminus. The binding 
of cytokine ligands results in dimerization of receptor subunits, thus increasing the local 
concentration of Jaks and bringing these kinases into close proximity. The Jaks become 
activated as a result of tyrosine phosphorylation and initiate the signal transduction cascade 
by phosphorylation of tyrosine motifs present in receptor cytoplasmic domains and in 
receptor-associated proteins. Phosphotyrosine- containing motifs in receptor cytoplasmic 
domains act as docking sites for many signaling proteins, including STATs (Figure 2) (17).  
The JAK-STAT cascade is regulated by positive and negative effectors. Activators include 
signal-transducing adapter molecules (STAMs) and proteins containing SH2 domains, while 
inhibitors include suppressors of cytokine signaling (SOCS) and tyrosine phosphatases (18, 
19). 
	 	 Introduction 
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Figure 2. Cytokine activation of the Jak-STAT pathway (17). 
 
 
 
 
1.5.  Biology of STATs and inborn errors of human STATs 
 
STATs are existent in the cytoplasm of most cells as latent monomeric proteins. After 
cytokine binding of receptors, STATs are recruited to the receptor signaling complex by 
interactions between STAT Src homology 2 (SH2) domains and specific receptor 
phosphotyrosine sequences. One important determinant of the specificity of STAT activation 
by individual receptors is the affinity and specificity of the SH2–phosphotyrosine interaction 
(20). Once recruited to the receptor, STATs themselves are phosphorylated on a unique 
conserved carboxy-terminal tyrosine. Tyrosine phosphorylation of STATs is associated with 
dissociation from the receptor and the formation of STAT: STAT dimers, which is mediated 
by reciprocal SH2–phosphotyrosine interactions between the dimer partners. STATs acquire  
DNA-binding activity through dimerization and then translocate to the nucleus where they 
bind to gene promoters and activate transcription (20). 
There are seven mammalian STATs: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, 
and STAT6. 
	 	 Introduction 
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1.5.1.  STAT1 
 
STAT1 is a key signaling component of IFN responses (17, 21). There are 2 STAT1 mRNAs, 
STAT1A (25 exons ) and (STAT1B 23 exons) which use distinct polyadenylation sites 
(Figure 3) (22, 23). Following IFN-α stimulation, the heterodimeric IFN-α receptor is 
phosphorylated by the associated JAK1 and TYK2, generating a docking site for a single 
STAT2 molecule which is in turn phosphorylated (Figure 4). One latent STAT1 molecule is 
recruited by phosphorylated STAT2 and phosphorylated on its Tyr701 residue (22). Active 
phosphorylated heterodimers STAT1/STAT2 are released into the cytosol, combining with 
IFN-stimulated gene factor 3 γ (ISGF3-γ), also known as p48 or IRF9, to form ISGF3 (Figure 
4). ISGF3 is translocated to the nucleus and binds to IFN-α sequence response elements 
(ISREs) in the promoters of target genes (22–24). In contrast, IFN-γ stimulation leads to 
activation of the associated JAK1 and JAK2, leading to at the end to form pSTAT1 
homodimers, forming gamma-activating factor (GAF) (Figure 4). GAF is translocated to the 
nucleus, where it binds to gamma-activating sequences (GASs) in the promoters of target 
genes and activates transcription (Figure 4) (23). 
 
 
 
 
 
Figure 3. Structural domains and phosphorylation sites of STAT1  (22). 
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Figure 4. IFNs activation of the STAT1 pathway (25). 
 
Human mutations in STAT1 were first identified in human patients with Mendelian 
predisposition to mycobacterial diseases (MSMD) (Table 1). MSMD is characterized by the 
occurrence of clinical disease caused by weakly virulent mycobacteria in otherwise healthy 
patients (26, 27). The heterozygous L706S STAT1 mutation in the tail segment domain of 
STAT1 (Figure 3) impairs Tyr701 phosphorylation, preventing the formation of ISGF3 and 
GAF complexes following stimulation with IFN-α and IFN-γ, respectively (26, 27). 
Heterozygous STAT1 mutations E320Q and Q463H in the DNA-binding domain of STAT1 
(Figure 3) impair ISGF3 and GAF binding to ISREs and GAS elements upon IFN-α and IFN-
γ stimulation, respectively (26, 27). However, MSMD was observed in two forms: autosomal 
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dominant (AD) MSMD associated with a partial STAT1 deficiency and autosomal recessive  
(AR) form associated with a complete STAT1 deficiency (28).  
In 2011, heterozygous gain-of-function STAT1 (GOF) mutations (OMIM # 614162) were 
described as the major cause of chronic mucocutaneous candidiasis disease (CMCD) (Table 
1) (29). Patients with CMCD suffer from persistent or recurrent skin, nail and mucosal 
membrane infections caused by C. albicans. Heterozygous mutations affecting of STAT1 
were identified recently by next-generation sequencing in patients with autosomal-dominant 
CMCD. These mutations led to increase in Tyr701-pSTAT1, gain –of- function DNA-binding 
ability and IFN - γ-activating sequence transcription activity in response to IFN- γ, IFN- α, 
and IL-27 (30, 31).  
 
Table 1. STAT- related disorders (32). 
 
  
STAT Activating Cytokines Disorders caused by 
loss-of-function n 
Mutations 
Disorders caused by 
Gain-of-function n 
Mutations 
STAT1 Interferons, other 
cytokines 
Mycobacterial infections, 
viral infections  
Chronic mucocutaneous 
candidiasis, fungal 
infections, aneurysms 
STAT3 Interlukin-6 and many 
other interleukins 
Hyper- IgE syndrome Large granular leukemia, 
ABC diffuse large B- cell 
lymphoma, other cancers 
STAT5A Prolactin, Interlukin-2, 
other cytokines 
 Multiple cancers 
STAT5B  Growth hormone, 
Interlukin-2, other 
cytokines 
Immunodeficiency, 
growth failure, 
autoimmunity 
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1.5.2.  STAT3 
 
STAT3 is one of the STATs families. In non-activated cells, STAT3 like other STATs 
proteins, is kept in an inactive cytoplasmic form (33). Then, once activated, STAT3 
translocate into the nucleus where it behaves as a transcription activator for a broad array of 
targeted genes. Characteristically, STAT3 activation is stimulated by phosphorylation on a 
critical tyrosine residue (Tyr 705) that triggers STAT3 dimerization as a result of reciprocal 
phosphotyrosine-SH2 domain interactions (Figure 5). The phosphorylation of STAT3 on 
tyrosine 705 is mainly regulated by members of Janus-activated kinases with JAK1 as key 
modulator. In addition to tyrosine 705 phosphorylation, STAT3 is also activated through 
serine (Ser 727) phosphorylation (Figure 5). STAT3 is pleiotropic and can be activated by 
multiple cytokines including IL-6, IL-10, and IFN-α/β (Figure 6) (34). It is now well 
established that STAT3 signaling is a major intrinsic pathway driving apoptosis, 
inflammation, cellular transformation, survival, proliferation, invasion, angiogenesis, and 
metastasis of cancer (33). 
 
 
 
Figure 5. Structural domains and phosphorylation sites of STAT3 (35). 
 
 
The function of STAT3 is critically dependent on the cell type. STAT3 -deficient T-cells 
exhibit a poor response to IL-6 (36). STAT3 is important in IL-6-mediated suppression of 
apoptosis and potentiates proliferation through this mechanism (Figure 6) (37). STAT3 
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deficiency in macrophages and neutrophils is associated with exaggerated production of 
cytokines presumably due to impaired IL-10 responsiveness (36), resulting in hyperactivation 
of macrophages, marked increases in inflammatory cytokine production and inflammatory 
bowel disease, demonstrating the immune-suppressive and anti-inflammatory function of 
STAT3 in the myeloid lineage (38).  
 
 
 
Figure 6. IL-6 and IL-10 activation of the STAT3 pathway (39). 
 
Deletion of STAT3 during hematopoiesis results in abnormalities in myeloid cells, leads to 
overactivation of innate immune responses and causes inflammatory bowel disease-like 
pathogenesis (40). Recent studies highlighted the multiple and critical roles played by STAT3 
in humans in vivo and provide important information for the physician taking care of patients 
with hyper-IgE syndrome (HIES) (30). The search for the genetic cause of the autosomal 
dominant hyper-IgE or Jobs syndrome (# 147060 and # 243700 in the Online Mendelian in 
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Man human genetic disease database) culminated in the surprising identification of dominant- 
negative mutations in STAT3 (32). 
HIES is characterized by eczema, staphylococcal boils, cyst-forming pneumonias, chronic 
mucocutaneous candidiasis and extremely high levels of IgE along with numerous non 
immunologic features (32). The mutations that cause this complex multisystem 
Disease, are located mainly in the DNA-binding and Src homology 2 (SH2) domains of 
STAT3, leading to interference with the functioning of the normal allele. 
The identification of STAT3 as a major causative gene for type 1 HIES enables to definitively 
diagnose the HIES patients very early in life (41). Earlier definitive diagnosis at the DNA 
level facilitates the early start of prophylactic antibiotics, which is likely to prevent the 
pneumatocele formation. Preventive action should improve the quality of life of the HIES 
(41). 
1.5.3.  STAT5  
 
STAT5 refers to two proteins: STAT5A and STAT5B, which share 94% structural homology 
but are transcribed from separate genes. As shown in Figure 7, STAT5A consists of 793 
amino acids (94kD) while STAT5B consists of 786 amino acids (92kD) in murine species 
(42). The most significant difference between STAT5A and STAT5B is 20 amino acids in the 
transactivation domain (TAD) of STAT5A, as denoted by the pink bar in Figure 7. Both 
STAT5A and STAT5B are activated by phosphorylation at Tyr694 and Tyr699, respectively, 
by JAKs, which is activated by a wide range of cytokines (Figure 8) (43). 
In mammals, STAT5 proteins have been associated with many functions including cell 
differentiation , lipid mobilization and lymphocyte development (42, 44–47). 
T cells from STAT5A deficient mice have decreased proliferation secondary to diminished 
expression of the IL-2Rα chain (48). STAT5B- deficient mice have a more significant 
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proliferation defect that cannot be corrected by high-dose IL-2 and decreased numbers of NK 
cells with diminished cytolytic activity (17, 42). 
STAT5A/B double knockout mice have also hypocellular bone marrow, lymphopenia,  
neutrophilia, modest anemia, thrombocytopenia, reduced numbers of B-cell precursors and 
mature B-cells (36). However, peripheral T cells from these mice express constitutively 
activation markers but show impaired proliferative response to TCR/IL-2 stimulation (36). 
Activated STAT5 has been found in several malignancies (36). In hematopoietic cells, 
STAT5 has been demonstrated to play a critical role in regulating apoptosis and in promoting 
proliferation and cell cycle progression (36). 
 
 
 
 
Figure 7. Structural domains and phosphorylation sites of STAT5 (42).  
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Figure 8. Cytokines activation of the STAT5 pathway (43). 
 
1.6.  IL-2-JAK3- STAT5 Signal pathway 
 
 
IL-2 is a 15.5 kDa cytokine secreted by antigen-activated T cells, it is known as a T cell 
growth factor (49). IL-2 is now known to have a wide range of actions, including the ability to 
induce the cytolytic activity of NK, increase the cytolytic activity of tumor-infiltrating 
lymphocytes (TILs), augment immunoglobulin production by activated B cells, maintain 
homeostatic proliferation of Treg cells and modulate effector T cell differentiation, as well as 
having actions on memory T cells, effector T cells and monocytes (49). 
IL-2 activates three main signaling pathways, including the JAK-STAT pathway (mainly 
activating JAK1, JAK3, STAT5A, and STAT5B), the RAS-MAP kinase pathway and the PI 
3-kinase/AKT pathway (50). Upon IL-2 binding, dimerization of IL-2R𝛽 and 𝛾c results in 
JAK kinase activation, resulting in phosphorylation of IL-2R𝛽 and thereby creating 
phosphotyrosine docking sites for the SH2 domains of STAT5 proteins (Figure 1) (49). 
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STAT5 proteins in turn are then phosphorylated, dimerize and translocate into the nucleus 
where they modulate gene expression, differentiation, survival and cellular function (49). 
The production of IL-2 is tightly regulated and largely restricted to the activated CD4+ T cells 
(50). IL-2 secreted by activated CD4+ T cells also can act in a paracrine manner on other 
immune cells, including Treg cells which produce little if any IL-2.  
Interestingly, Treg cells constitutively express high-affinity IL-2 receptors, which enable them 
to efficiently respond even to low concentrations of IL-2. Other populations of cells, 
including activated CD8+ T cells, NK T cells and dendritic cells also have been reported to 
secrete IL-2, albeit at much lower levels than activated CD4+ T cells (51) . 
Defects in either IL-2 production or in IL-2-mediated signaling have been associated with 
autoimmune diseases, resulting from the failure to maintain normal Treg cell numbers and 
leading to altered tolerance (50). 
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1.7. The rationale for the study 
 
As described above, JAK-STATs signaling pathways play an important role in T cell 
activation and proliferation, therefore understanding their molecular basis has been of great 
interest in both the purpose of basic research and the expansion of our understanding of the 
disease pathogenesis and development of new therapies. STATs proteins have been studied 
by different methods such as genome sequencing and Western blot (WB), which are limited 
due to its time-consuming nature and the requirement of extensive cell numbers (52). Today, 
flow cytometry has increasingly become a tool of choice for the analysis of cellular phenotype 
and function in the immune system. It is arguably the most powerful technology available for 
assessing not only the expression of cell-surface proteins, but also that of intracellular 
phosphoproteins and cytokines as well as other functional readouts (53). 
Based on this knowledge, we decided to investigate and evaluate weather flow cytometric-
assay of STATs phosphorylation can be used as a fast-appropriate approach to detect the 
STATs activation, especially STAT1 and STAT3-associated immunodeficiencies in T cell 
population.  
Furthermore, given the basic role of STAT5A phosphorylation in T cell proliferation, we 
asked whether phosphorylation of STAT5A is a fast worthful approach to predict T cell 
proliferation upon activation with mitogens and antigens. Proliferation and clonal expansion 
of antigen-specific T cells are critical functions for mediating protective immunity and 
immunological memory (54). Today, T cell proliferation assays are mainly carried out by 
flow cytometric techniques such as fluorescent dye dilution assays, using carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) or its derivative, Oregon Green, which is partitioned  
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with remarkable fidelity between daughter cells allowing 8 to 10 discrete generations to be 
identified (54, 55). 
The current assays have many drawbacks including the fact that they are quantitative methods 
which provide no specific information on cell biology. Furthermore, they require a prolonged 
culture time and an extensive number of cells, making the assay is labor- and resource-
intensive and requiring several days (3–7 days). This is especially inconvenient when rapid 
diagnosis is desirable; hence, a fast and simple flow cytometric method enabling the early and 
reliable detection of lymphocyte entry into an activation program would be of great interest.
Objectives 
20 
 
2. Objectives 
 
1. Introduction of the flow cytometric immunophenotyping as well-standardized and 
flexible method for precise identification and characterization of cells and their 
function (Publication I).  
2. Establishment and validation of a fast flow cytometric whole blood assay to evaluate 
STAT1 and STAT3 phosphorylation as a fast and sensitive marker to investigate 
STAT1 and STAT3 associated immunodeficiencies diseases (Publication II). 
3. Establishment and validation of a fast and sensitive flow cytometric based pSTAT5A 
assay to detect CD3/CD28 and PHA stimulated T cell proliferation (Publication III). 
4. Establishment and validation of a fast and sensitive flow cytometric based pSTAT5A 
assay to detect CMV specific T cell proliferation (Publication IV). 
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Supplementary Figure 1. Flow cytometric gating strategy to detect STAT5A 
phosphorylation and CD25+ T cells. Peripheral blood cells (1 * 106 cells/ml) were stimulated 
with CD3/CD28 (100 ng/ml) or PHA (10 µg/ml). After 24 h, T cells were stained with PerCP-
Cy TM 5.5 (mouse anti-human CD3), PE (mouse anti-human CD25), Alexa Fluor 647 (mouse 
anti human -STAT5A) according to the manufacturer’s instructions (BD Biosciences, 
Heidelberg, Germany). Based on the following gating strategy forward scatter (FSC) vs. side 
scatter (SSC) and (2) CD3 vs. SSC (B), the T cells (CD3+) were separated. CD25+ CD3+ cells 
were detected by dot plot as CD25 PE vs. CD3 PerCPCy5.5 (C) and pSTAT5A as histogram 
(D). Mouse IgG1-k- Alexa Fluor 647 was used as an isotype control for assessing the 
background staining of the cells.  
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Supplementary Figure 2. Flow cytometric gating strategy to detect proliferating 
T cells. Peripheral blood cells (1 * 106 cells/ml) were stimulated with CD3/CD28 (100 ng/ml) 
or PHA (10 µg/ml). After 72 h, the T cells were stained with APC–H7 (mouse anti-human 
CD45 clone 2D1, 2.5 µl), FITC (mouse anti-human CD3, clone SK7, 5 µl,) and 7-Amino-
Actinomycin D (7-AAD). Based on the following gating FSC vs. SSC (A) and CD45 vs. SSC 
(B) (mathematical connected by AND-operation) the T cells (CD3+) were separated in a third 
dot plot (CD3 vs. SSC) (C). Live T cells were detected by dot plot (CD3 vs. 7AAD) (D).  The 
decrease of VPD450 dyes intensity in proliferating CD3+ cells (E). 
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Supplementary Figure 3. Time dependent phosphorylation of STAT5A and determination of 
IL-2 production. PBMCs (1 * 106 cells/ml) were stimulated either with (A) CD3/CD28 (100 
ng/ml) or (B) (C) PHA (10 µg/ml) for different times (0, 6, 12, 24, 48, 72 h). MFI of 
pSTAT5A was analyzed (A) and (B) and supernatants were collected, and IL-2 concentration 
was determined by EIA (C). Each point represents the mean ± SD; *, p < 0.05 **, p < 0.001; 
MFI, median fluorescence intensity. 
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Abstract 
Cytomegalovirus (CMV) specific T cells expand with CMV reactivation and are probably 
prerequisite for control and protection. 
This study presents a simple and sensitive flow cytometric-based assay to assess CMV 
specific T cell proliferation. Given the critical role STAT5A phosphorylation in T cell 
proliferation, we decided to assess pSTAT5A as an indicator of CMV specific T cell 
proliferation. We determined pSTAT5A in T cells treated with CMV specific peptide mix 
(pp65 + IE1 peptides) from 20 healthy adult subjects and three patients with CARMIL-2 
mutation. After stimulation, T cells from eleven CMV-seropositive (CMV+) subjects showed 
a long-lasting phosphorylation of STAT5A for 24 hours. The percentage of pSTAT5A+ T 
cells significantly increased from 3.0 ± 1.9% (unstimulated) to 11.4 ± 5.9% (stimulated) for 
24 hours. After seven days of stimulation, the percentage of expanded T cells amounted to 26 
± 17.2%. Conversely, the percentage of pSTAT5A+ T cells and T cell proliferation from nine 
CMV-seronegative (CMV-) subjects hardly changed (from 3.0 ± 1.3% (unstimulated) to 3.7 ± 
1.8% (stimulated) and from 4.3 ± 2.1% to 5.7 ± 1.7% respectively). Furthermore, we showed 
a positive correlation between the percentage of pSTAT5A+ T cells vs. (1) CMV-IgG 
concentrations (r = 073; p < 0.0001) vs. (2) the percentage of expanded T cells (r = 0.8; p < 
0.0001) and vs. (3) the percentage of initial CMV specific T cells (r = 0.5; p < 0.01). In 
CARMIL-2 patients, CMV specific pSTAT5A and T cell proliferation were completely 
deficient. 
In conclusion, pSTAT5A represents an appropriate diagnostic tool to rapidly identify CMV 
specific T cell proliferation and helps to understand dysfunctions in controlling CMV 
infections.  
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Introduction   
 
Human cytomegalovirus (CMV) infection is a common pathogen that often results in an 
asymptomatic infection (1). In healthy CMV-infected individuals, pathogenesis is controlled 
by the CMV specific T cells involving both CD4 and CD8 T cells. Loss or suppression of 
adaptive immunity as accrues in primary and secondary immune deficiencies, transplant 
patients, or older people who suffer from age-associated changes in the immune system, 
frequently leads to CMV reactivation (2–11). CMV specific T cells expand with CMV 
reactivation and are probably prerequisite for control and protection (12). Today, flow 
cytometric CMV specific T cell proliferation assay is based on the measurement of cell 
proliferation by serial halving of the fluorescence intensity of the vital dye (9). As initial 
CMV specific T cell numbers vary from subject to subject, a prolonged culture time and an 
extensive number of cells are required to expand it, making the assay is labor- and resource-
intensive and requiring several days (5–7 days) (8, 10, 11, 13). These drawbacks might be 
impractical for routine diagnostic purposes, specifically when an early diagnosis is required. 
Therefore, a rapid and simple flow cytometric assay enabling the early and reliable detection 
of CMV specific T cells entry into an activation program is of particular interest. As 
previously described (14), upon T cell receptor (TCR) activation, T cell proliferation strongly 
depends on the phosphorylation of the signal transducer and activator of transcription 5A 
(pSTAT5A). The phosphorylation of STAT5A occurs within 24 hours and can be used as an 
early marker to assess mitogen-driven T cell proliferation (14). Based on this knowledge, the 
aim of the present study is to establish a rapid flow cytometric CMV specific pSTAT5A assay 
to serve as a prediction marker for CMV specific T cell proliferation. We analyze and 
compare pSTAT5A and T cell proliferation in T cells treated with a CMV specific peptide 
mix (pp65 + IE1 peptides) from CMV+ and CMV- seronegative (CMV-) healthy subjects and 
show a strong correlation between the two events. Subsequently, to examine the accuracy of 
our results, we compare the measurement established here with peptide-MHC tetramer 
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analysis. Moreover, we verify this assay by analyzing pSTAT5A in T cells from three 
CARMIL-2- patients suffering from chronic CMV infection. Human CARMIL-2 deficiency is 
an autosomal recessive primary immunodeficiency disease associated with a deficiency of 
regulatory T cells and defective CD28 signaling, which leads to impaired T-cell stimulation, 
differentiation, and proliferation (15). Given its simplicity and robustness, the flow cytometric 
based pSTAT5 assay is especially appropriate to rapidly assess CMV specific T cell 
proliferation. 
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Methods and Material  
Collection of blood samples 
Blood was taken from 20 healthy adult subjects for the serological, immunological, and 
genetic analyses at the Institute of Clinical Immunology, University of Leipzig Medical 
Center. In addition, we analyzed T cells from three patients (P 1; P 2-1; P 2-2) with CARMIL-
2 mutation. After informed consent from the ethics committee of University Leipzig 
(092/2002 and 151/2006) was obtained, peripheral blood samples and data were collected 
from patients and normal controls. This study protocol was approved by the University of 
Leipzig Medical Center. 
Cytomegalovirus serology 
Human serum was separated by centrifugation for 10 minutes at 600 x g and frozen at – 80°C. 
CMV-IgG levels were determined by ARCHITECT CMV IgG assay (Abbott Laboratories, 
Dublin, Ireland) at the Institute of Virology, University of Leipzig Medical Center. The cut-
off was determined to be positive at concentration > 7.0 AU/ml. 
 
Isolation of PBMCs and staining with violet proliferation dye 450 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh lithium-heparinized 
peripheral blood samples by density centrifugation over Ficoll-Hypaque (Pan Biotech, 
Germany), as described previously (14, 16, 17). PBMCs (1 * 107 cells/ml) were diluted with 
phosphate-buffered saline (PBS, pH 7.2) (Gibco life Technologies, Carlsbad, USA) and 
stained with violet proliferation dye 450 (VPD450) (3 µM) (BD Biosciences, San Jose, USA) 
for 15 minutes at 37 °C. Subsequently, PBMCs were washed and re-suspended in RPMI 1640 
containing 10% fetal bovine serum, penicillin (1 * 105 mg/ml), and streptomycin (1 * 105 
mg/ml) (Gibco life Technologies, Carlsbad, USA) and finally adjusted to 3 * 106 cells/ml. 
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PBMCs stimulation   
PBMCs (3 * 106 cells/ml) were seeded into 48 well cell culture plates (75 * 105 cells/well) at 
37 °C. Afterwards, PBMCs were stimulated with the major target antigens of CMV specific 
peptide mix (1µg/ml) consisting of pool of Pp65 + IE1 peptides (ELSP5944, AID, Germany) 
as previously described (4, 18, 19), with CD3/CD28 (100 ng/ml) (eBioscience clones OKT3, 
CD28.2) as a means of positive control or with IL-2 (100 ng/ml) (BD Biosciences, 
Heidelberg, Germany). Simultaneously, cells were cultured for 24 hours or seven days in a 
humidified atmosphere of 5% CO2 at 37 °C to determine pSTAT5A and T cell proliferation, 
respectively.  
Determination of CMV stimulated pSTAT5A+ T cells by flow cytometry 
The cultivated PBMCs were harvested after 24 hours, pelleted by centrifugation, lysed and 
fixed by using “lyse and fix” buffer (BD Biosciences), and incubated at 37 °C in a water bath 
for 12 minutes. The cells were centrifuged, the supernatant was discarded, and the pellet was 
washed with 4 mL PBS. 
The samples were permeabilized by using cold perm buffer III (1 ml) (BD Biosciences) and 
were left on ice for 30 minutes. The pellet was washed with a fetal bovine serum stain buffer 
(FBS) (2 ml) (BD Biosciences) and finally re-suspended in 200 µl FBS. For flow cytometric 
analysis, the T cells were stained with PerCP-Cy TM 5.5 mouse anti-human CD3 (2.5 µl, 
clone UCHT1, BD Biosciences) and Alexa Fluor 647 mouse anti-human STAT5A 
phosphorylation (10 µl, PY694, Clone 47/Stat5, BD Biosciences). Mouse IgG1-k- Alexa 
Fluor 647 was used as an isotype control for assessing the background staining of the cells. 
After one hour of incubation in the dark at room temperature, the cells were washed with 2 ml 
stain buffer, centrifuged and were suspended in 300 µl of stain buffer. FACSCanto II based 
flow cytometry was conducted to measure the samples. Briefly, the system was set up with 
three lasers: a violet laser 405 nm, a blue laser 488 nm, and a red laser 647 nm (20, 21). Prior 
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to running samples, the instrument was calibrated using calibration beads (BD Biosciences). 
BD FACSDiva software was used for acquisition of the events (21).  
The analysis of the pSTAT5A is based on the following gating strategies: (1) forward scatter 
(FSC) vs. side scatter (SSC), (2) FSC area (FSC-A) vs. FSC height (FSC-H) (singlets gate), 
and (3) CD3 vs. SSC. After the conduction of the previous gating strategies, the T cells 
(CD3+) were separated. Now, after a clear separation of T cells from the non-T cells, 20,000 
CD3+ T cells per sample were acquired. The expression of pSTAT5A was calculated as a 
percentage of pSTAT5A+ T cells (supplementary Figure 1). 
Determination of CMV stimulated T cell proliferation by flow cytometry  
Cultivated PBMCs were harvested after seven days and washed with 2 mM EDTA PBS. The 
pellet was re-suspended in 200 µl PBS and stained with FITC mouse anti-human CD3 (5 µl, 
clone SK7, BD Biosciences) at 37 °C. After 15 minutes, cells were washed with 2 ml 2 mM 
EDTA PBS, centrifuged, and suspended in 300 µl PBS. 7-Amino-Actinomycin D staining (7-
AAD) (10 µl, BD Biosciences) was added to pre-stained T cells for 10 minutes before the 
measurement was conducted. 7-AAD used to determine cell viability. The analysis of the T 
cell proliferation is based on two lymphocyte gates (1) FSC vs. SSC and (2) FSC-A vs. FSC-
H (singlets gate) where CD3+ live cells (T cells) were separated in a third dot plot (CD3 vs. 7-
AAD). Now, the decrease of VPD450 dye intensity in expanded CD3+ cells was measured 
and 50,000 CD3+ cells per sample were acquired (supplementary Figure 2). The data analysis 
was conducted using FlowJo.7.6.5 software (Ashland, OR, USA) (22). 
HLA-A2 genotyping and Peptide-MHC tetramer binding analysis 
Three subjects enrolled in the study their samples were analyzed by Peptide-MHC tetramer 
staining. Blood samples were tested for HLA-A* 02 by genotyping at the Institute of 
Transfusion Medicine at the University of Leipzig Medical Center. Peptide-MHC tetramer 
staining was performed on PBMC using 5*106 cells per individual tetramer analysis. 
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HLA-A*02-restricted CMV peptide-HLA tetramers (VLEETSVML IE-1316-324 and 
NLVPMVATV pp65495-503) were multimerized with either Streptavidin BV421 or 
Streptavidin APC (ThermoFischer Scientific, Waltham, USA) 40µg/ml HLA molecules and 
25µg/ml Streptavidin for 50 minutes on ice at the Institute of Microbiology, Immunology and 
Hygiene of the Technical University of Munich. Afterwards, 5*106 PBMCs per epitope were 
stained with Streptavidin BV421 for 40 minutes on ice and then 5*106 PBMCs were stained 
on ice in a total volume of 100 µl 1% bovine serum albumin/phosphate-buffered saline (PBS) 
containing CD45RA_FITC, CD8_PE, CD19_ECD, CCR7_PE-Cy7, CD3_PacificOrange 
(ThermoFischer Scientific, Waltham, USA) and APC multimers for 30 minutes. 
Cells were washed using 1% BSA/PBS and before analysis 1µg/ml propidium iodide (PI) 
(ThermoFischer Scientific, Waltham, USA) was added. Multiparameter flow cytometry was 
performed on a CytoFlex equipped with a 488 nm, 405 nm and 630 nm Laser operated with 
the CytExpert Software Version 2.2 (Beckman Coulter, Inc., Fullerton, USA). CD3+, CD8+ 
CMV tetramer-positive cells were identified by gating on single living lymphocytes using PI 
live/dead discrimination. B cells were excluded by CD19_ECD dump staining. A double 
multimer staining on BV421 and APC for the same epitope reduced staining artefacts. T cell 
antigen experience was determined by CCR7 and CD45RA staining. Data were analyzed 
using FlowJo Version 10.6.1 (BD Bioscience, Franklin Lakes, USA). 
 
Determination of IFN-γ and TNF-α production in CMV stimulated T cells 
PBMCs from 3 subjects (3 * 106 cells/ml) were cultured with CMV specific peptide mix 
(1µg/ml) (ELSP5944, AID, Germany) or with CD3/CD28 (100 ng/ml) (eBioscience clones 
OKT3, CD28.2) for 24 hours. The cell supernatants were then collected and assayed for IFN-γ 
and TNF-α by enzyme immunoassay (EIA; R&D system, Minneapolis, USA). 
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Adaptation of methods to DIN EN ISO 15189 requirements 
 The international standard DIN EN ISO 15189 suggested proceedings (performing intra-
assay and inter-assay precision) to fulfill highest requirements for the quality and competency 
of medical laboratories to exclude or diminish false positive or false negative results (21, 23). 
Please note that in case of using two or more different FACSs, differences in technical 
adjustments among different devices leading to various results in the mean fluorescence 
should be considered. Therefore, a transfer of the instrument setting among the devices has to 
be performed. 
Statistical analysis 
The statistical analysis was performed using the Graph Pad Prism 5 software (graph Pad 
Prism software, Inc., San Diego, CA, USA) and Sigmaplot.14.0 software (Systat Software 
Inc, San Jose, CA). The adjusted P-values were estimated by Wilcoxon’s test (Ns not 
significant, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). Correlation analysis was used to identify 
Spearman`s correlation coefficient (r). The receiver operating characteristic (ROC) curve was 
plotted to evaluate the sensitivity, specificity, and area under the curve (AUC) value of the 
system. 
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Results 
Cytomegalovirus serology 
 
CMV-IgG concentrations in subjects enrolled in the study were accurately determined. Eleven 
of the 20 healthy subjects tested positive for CMV-IgG. The samples were considered positive 
if the CMV- IgG level is higher than 7.0 AU/ml (Table 1). 
 
Time dependent STAT5A phosphorylation  
 
To determine the optimal time to typically analyze the percentage of pSTAT5A+ T cells, we 
performed a series of kinetics. We found that the CMV (1µg/ml) stimulated pSTAT5A could 
be reliably detected after six hours of stimulation and reached a peak value after 12 hours. It 
declined thereafter (supplementary Figure 3A). Clearly, production of IFN-γ and TNF-α 
correlated with pSTAT5A after 24 h (Supplementary Figure 3B, C respectively). Because of 
difficulties in maintaining the working routine of the laboratory, we analyzed pSTAT5A after 
24 hours. 
 
Determination of the percentage of CMV stimulated pSTAT5A+ T cells  
 
CMV stimulated T cells from CMV+ subjects showed a significant increase in the percentage 
of pSTAT5A+ T cells (from 3.0 ± 1.9% (unstimulated) to 11.4 ± 5.9% (CMV)) at 24 hours 
(Figure 1A). Conversely, the percentage of pSTAT5A+ T cells from CMV- subjects hardly 
changed (from 3.0 ± 1.3% (unstimulated) to 3.7 ± 1.8% (CMV)) at 24 hours (Figure 1B). 
The ROC curve was plotted to determine the specificity, sensitivity, and AUC value of the 
assay.  As shown in Figure 1C, when the percentage of pSTAT5A+ T cells cut-off value was 
set to 9.1(pre-test probability 0,5, Cost ratio 1.0), the ROC curve gave an AUC of 0,88 (p < 
0.004) with a specificity and sensitivity of 100% and 73%, respectively. 
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Figure 1. CMV stimulated pSTAT5A profile in seropositive (CMV+) and seronegative 
(CMV-) subjects. PBMCs (3 * 106 cells/ml) were stimulated with CMV specific peptide mix 
(1µg/ml). After 24 hours, the percentage of pSTAT5A in T cells was measured. (A)  The 
percentage of CMV stimulated pSTAT5A+ T cells in CMV+ subjects; (B) The percentage of 
CMV stimulated pSTAT5A+ T cells in CMV- subjects; (C) The receiver operating 
characteristic (ROC) curve was plotted to evaluate the sensitivity, specificity, area under the 
curve (AUC) of the assay, and to determine % pSTAT5A+ T cells  cut-off value. when % 
pSTAT5A+ T cells cut-off value was set to 9.1, the Roc curve gave an AUC of 0.88 (p < 
0.004) with a sensitivity (73%) and specificity (100%). Ns, non-significant; **, p < 0.01 
(Wilcoxon’s test). 
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Determination of the percentage of expanded T cells and the initial CMV specific T cells  
Furthermore, after seven days as determined by VPD450 dye staining, CMV specific T cells 
from CMV+ subjects expanded from 4.9 ± 4% to 26 ± 17.2% after antigen stimulation (Figure 
2A). In contrast to CMV+ subjects, the percentage of expanded T cells from CMV- subjects 
hardly changed (from 4.3 ± 2.1% (unstimulated) to 5.7 ± 1.7% (CMV)) (Figure 2B). The 
percentage of initial CMV specific T cells was 6 ± 8.2% in the original population from 
CMV+ subjects, as calculated with FlowJo.7.6.5 software (Figure 2C).  
There was a significant difference between CMV+ and CMV- subjects in relation to the 
percentage of initial CMV specific T cells (Figure 2C). 
 
 
 
 
Publication IV 
77 
 
 
Figure 2. Analysis of CMV specific T cell proliferation and initial CMV specific T cells from 
CMV+ and CMV- subjects. PBMCs (3 * 106 cells/ml) were stimulated with CMV specific 
peptide mix (1µg/ml). After seven days, the percentage of expanded T cells was measured. 
(A) The percentage of expanded T cells from 11 CMV+ subjects (B) The percentage of 
expanded T cells from 9 CMV- subjects; (C) Comparison of the percentage of initial CMV 
specific T cells (CMV+ T cells) in CMV- and CMV+ subjects. Ns, non-significant; **, p < 0.01 
(Wilcoxon’s test). 
 
Correlation between the percentage of pSTAT5A+ T cells, CMV-IgG concentrations, the 
percentage of expanded T cells and the percentage of initial CMV specific T cells 
A strong correlation was observed between the percentage of pSTAT5A+ T cells with; (1) 
CMV-IgG concentrations (r = 0.73, p < 0.0001) (2) the percentage of expanded T cells (r = 
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0.8, p < 0.0001), and (3) the percentage of initial CMV specific T cells (r = 0.55, p = 0.01) 
(Figure 3A, B, C respectively). 
 
 
Figure 3. Correlation between the percentage of pSTAT5A+ T cell with the concentration of 
CMV- IgG, the percentage of expanded T cells and the percentage of initial CMV specific T 
cells (CMV+ T cells). (A) The percentage of pSTAT5A+ T cells and CMV-IgG; (B) The 
percentage of pSTAT5A+ T cells and the percentage of expanded T cells; (C) The percentage 
of pSTAT5A+ T cells and the percentage of initial CMV+ T cells. Spearman´s correlation 
coefficient (r).  
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Determination of CMV specific T cells by peptide-MHC tetramer analysis  
To examine whether the results were accurate, three selected donors (donor 1 (CMV-) and 
donors 2 and 3 (CMV+)) who enrolled in the study were also analyzed by peptide-MHC 
tetramer analysis. The results demonstrated that, in contrast to the CMV – donor, CMV 
specific CD8+ T cells from CMV+ donors were detected using peptide-MHC tetramers 
(Supplementary Figure 4).  
 
Validation of CMV stimulated STAT5A phosphorylation in 20 healthy adult subjects to 
DIN EN ISO 15189 requirements and for use in diagnostic application 
To ensure that our analysis is accurate, reproducible, and precise, validation of our data 
included the definition of intra- and inter-assay precision values (23). A coefficient of 
variation of up to 20 percent was considered tolerable and fulfilled the criteria of the 
International Standard EN ISO 15189 (data not shown). 
 
Evaluation of pSTAT5A profile at three patients with CARMIL2- mutations suffering 
from chronic CMV infection 
Subsequently, we verified the established measurement by CMV specific T cells stimulation 
in three selected patients diagnosed with CARMIL2-mutation and suffering from chronic 
CMV infection. 
Patient 1 (P 1, male) has consanguine parents. PCR analysis showed high CMV viral load. 
The profile of flow cytometric analysis demonstrated that most T cells were naïve or effector 
T cells, whereas memory T cells could not be detected. Our results demonstrated that after 24 
hours of stimulation, pSTAT5A was completely or partially deficient in CMV or CD3/CD28 
stimulation, respectively (Figure 4A, B, D, E). The complete and the partial deficiency of 
CMV and CD3/CD28 stimulated pSTAT5A correlated with the complete and the partial 
deficiency of CMV and CD3/CD28 stimulated T cells proliferation, respectively (Figure 5). 
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IL-2 stimulated T cells showed a regular phosphorylation of STAT5A (Figure 4 C, F). Trio-
exome sequencing revealed to CARMIL-2 mutation which is characterized by CD28 signaling 
deficiency. 
 
 
 
Figure 4. Flow cytometric analysis of pSTAT5A in T cells from a patient (p1) with CARMIL-
2 mutation compared to a healthy control sample. PBMCs (3 * 106 cells/ml) were stimulated 
(red histogram) with (A, D) CMV specific peptide mix (1μg/ml, 24 hours); (B, E) CD3/CD28 
(100 ng/ml, 24 hours); (C, F) IL-2 (100 ng/ml, 15 minutes) or unstimulated (blue histogram). 
Percentages of pSTAT5A+ T cells are detailed within the histogram boxes. 
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Figure 5. Flow cytometric analysis of T cell proliferation in PBMCs from a patient with 
CARMIL-2 mutation compared to a healthy control sample.  PBMCs (3 * 106 cell/ml) were 
stimulated with (B, E) CMV specific peptide mix (1μg/ml, 7 days); (C, F) CD3/CD28 (100 
ng/ml, 7 days) or (A, D) unstimulated. Percentages of expanded T cells are detailed within the 
histogram boxes. 
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Patients P 2-1 and P 2-2 were diagnosed with homozygous loss-of-function CARMIL-2 
mutation. Our results demonstrated that after 24 hours of stimulation, pSTAT5A was 
completely or partially deficient in CMV and CD3/CD28 stimulated T cells, respectively 
(Figure 6). The complete and the partial deficiency of CMV and CD3/CD28 stimulated 
pSTAT5A correlated with the complete and the partial deficiency of CMV and CD3/CD28 
stimulated T cells proliferation, respectively (Figure 7). 
 
 
Figure 6. Flow cytometric analysis of pSTAT5A in PBMCs from two patients (P 2-1, P 2-2) 
diagnosed with CARMIL-2 mutation compared to a healthy control sample. PBMCs (3 * 106 
cells/ml) were stimulated (red histogram) with (A, C, E) CMV specific peptide mix (1μg/ml, 
24 hours); (B, D, F) CD3/CD28 (100 ng/ml, 24 hours) or unstimulated (blue histogram). 
Percentages of pSTAT5A+ T cells are detailed within the histogram boxes. 
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Figure 7. Flow cytometric analysis of T cell proliferation in PBMCs from two patients (P 2-1, 
P 2-2) diagnosed with CARMIL-2 mutation compared to healthy control sample. PBMCs (3 * 
106 cells/ml) were stimulated with (B, E, H) CMV specific peptide mix (1μg/ml, 7 days); (C, 
F, I) CD3/CD28 (100 ng/ml, 7 days) or (A, D, G) left unstimulated. Percentages of expanded 
T cells are detailed within the histogram boxes. 
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Discussion 
 
One standard procedure to quantify cellular immune responses to antigens is based on 
the measurement of cell proliferation (24, 25). It is known that the number of initial CMV 
specific T cells in peripheral blood of CMV+ individuals varies from subject to subject, hence 
a prolonged culture time (5 to 7 days) and extensive cell numbers to expand it are required (7, 
8), which is inconvenient when a fast diagnosis is desirable. Based on our previous study (14), 
in the present study we attempted to introduce a rapid and straightforward flow-cytometric 
method for the assessment CMV specific T cell proliferation. We investigated whether the 
phosphorylation of STAT5A is an appropriate candidate for predicting CMV specific T cell 
proliferation.  
In this study, we demonstrated that a moderate expression of pSTAT5A begins after 6 hours 
of stimulation by CMV specific peptide mix in CMV+ subjects, which leads to CMV specific 
T cell proliferation after seven days. Conversely, T cells treated with CMV specific peptide 
mix from CMV- subjects did not respond. Our data displayed a strong correlation between the 
two events.  
These observations confirm that STAT5A phosphorylation mediates and plays an important 
role in CMV specific T cell proliferation. Moreover, we evaluated and studied the relation 
between the investigated markers and found a positive correlation between the percentage of 
pSTAT5A+ T cells vs (1) CMV-IgG concentrations vs. (2) the percentage of expanded T cells 
and (3) the percentage of initial CMV specific T cells.  
 In order to confirm the accuracy of results, we compared the method established here with 
peptide-MHC tetramer analysis and found that in CMV + subjects who had pSTAT5A+ T cells 
after stimulation with CMV antigens, the initial CMV T cells were also detected by peptide-
MHC tetramer analysis. Unfortunately, it was not possible to stain the pSTAT5 and peptide-
MHC tetramer in one panel. This could be either due to the multimerized agents not binding 
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to the TCR in the correct manner, or the intracellular staining procedure altered the epitope 
specific staining. 
Finally, we evaluated the diagnostic value of pSTAT5 assay and determined the percentage of 
pSTAT5A+ T cells cut-off value at which pSTAT5 assay has the greatest diagnostic potency.  
Our data showed that a cut-off value of 9.1 % could be used to assess CMV specific T cell 
proliferation with a specificity and sensitivity of 100% and 73%, respectively. 
By using this simplified protocol, we are able to measure CMV specific T cell proliferation 
earlier (within 24 hours) and this may reveal important information on T cell biology in 
comparison to other measurements of CMV specific T cell activation as a detection CD137 
stimulation (26), CD107a mobilization (27), mICAM-1 staining (28), and an intracellular-
cytokine staining (29). 
As an example, we described three CARMIL-2 patients with chronic CMV infection. The 
results showed that the complete and the partial deficiency of CMV and CD3/CD28 
stimulated pSTAT5A correlated with the complete and the partial deficiency of CMV and 
CD3/CD28 stimulated T cell proliferation, respectively. Importantly, the positive IL-2 
stimulated pSTAT5A in T cells from patient 1 excluded the defects in JAK3/STAT5 signal 
pathway (14). These results correlated with Trio-exome sequencing revealing to CARMIL-2 
mutation, which is characterized by CD28 signaling deficiency, impaired naïve T cell 
activation, proliferation, effector function, and deficient gain of T-cell memory (15). In 
agreement with other studies, Goldeck et al. 2013 (30) showed that lower phosphor-signal is 
identified due to lower CD28 expression impacting on TCR/CD28 signaling crosstalk which 
is essential for T cell activation. 
This implied that CMV specific pSTAT5A detection can be used as a fast-diagnostic tool to 
detect the regeneration and proliferation of CMV specific T cells without requiring several 
days of culture. CMV specific T cells proliferation critically influences viral replication 
specifically in the post-transplant period (4). Monitoring of CMV specific T cells may be 
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useful for identifying patients at risk of viral replication (4, 31, 32). These outcomes were 
variable and showed subject dependency. Theses variables would likely result in differences 
in human leukocytes antigen, epitope dominance, and variability in the relative number of 
CD3+ expressions and memory T cells (33). 
In conclusion, disorders in the TCR – IL-2 –JAK3/STAT5 signal pathway in T cells may 
result in insufficient response to pathogens. As this method is rapid, robust, and adaptable, 
FCM-based pSTAT5A profiling is an effective tool for clinical laboratory diagnostics [1] to 
understand the susceptibility to recurrent opportunistic infections, [2] to quickly identify 
patients who are at risk of viral replication, and to further improve clinical management of 
CMV infection e. g., after allogeneic stem cell transplantation and [3] to identify and 
characterize well-known PIDs such as CARMIL-2 mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication IV 
87 
 
Abbreviations: AUC, area under the curve; CMV, cytomegalovirus; CMV+, CMV 
seropositive; CMV-, CMV seronegative; MHC, major histocompatibility complex; PBMCs, 
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Tables 
 
Table Ι. CMV- IgG concentrations from healthy adult subjects. 
 
Group (n = 20) CMV- IgG concentrations 
(AU/ml) 
Result 
Subject #1 >250 + 
Subject #2 173,4 + 
Subject #3 85,5 + 
Subject #4 118,6 + 
Subject #5 0,0 - 
Subject #6 0,5 - 
Subject #7 0,2 - 
Subject #8 0,4 - 
Subject #9 201,0 + 
Subject #10 0,4 - 
Subject #11 0,9 - 
Subject #12 205,8 + 
Subject #13 59,2 + 
Subject #14 208,9 + 
Subject #15 155,0 + 
Subject #16 0,2 - 
Subject #17 0,5 - 
Subject #18 197,8 + 
Subject #19 5,6 - 
Subject #20 206,5 + 
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Supplementary Figure 1. Flow cytometric gating strategy to detect STAT5A 
phosphorylation (pSTAT5A). PBMCs (3 * 106 cells/ml) were stimulated with CMV-peptide 
mix (Pp65 + IE1) (1µg/ml). After 24 h, T cells were stained with PerCP-Cy TM 5.5 mouse 
anti-human CD3, Alexa Fluor 647 mouse-anti human STAT5A phosphorylation according to 
the manufacturer’s instructions (BD Biosciences, Heidelberg, Germany). The following 
gating strategy was done: (A) forward scatter (FSC) vs. side scatter (SSC) (lymphocytes); (B) 
FSC area (FSC-A) versus FSC height (FSC-H) (singlets); (C) CD3 vs. SSC (T cells); (D) 
PSTAT5A+ T cells were detected by dot plot as pSTAT5A Alexa Fluor 647 vs. CD3 
PerCPCy5.5; (E) Mouse IgG1-k- Alexa Fluor 647 was used as an isotype control for 
assessing the background staining of the cells. 
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Supplementary Figure 2. Flow cytometric gating strategy to detect T cells proliferation. 
PBMCs (3 * 106 cells/ml) were stimulated with CMV-peptide mix (Pp65 + IE1) (1µg/ml). 
After 7 days, the T cells were stained with FITC (mouse anti-human CD3, clone SK7, 5 µl,) 
and 7-Amino-Actinomycin D (7-AAD). The following gating was done (A) FSC vs. SSC 
(lymphocytes) and (B) FSC area (FSC-A) versus FSC height (FSC-H) (singlets), (C) CD3 
FITC vs. 7-AAD. Live T cells were detected by dot plot (CD3 vs. 7AAD). (D) Decrease of 
VPD450 dyes intensity in expanded CD3+ cells. 
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Supplementary Figure 3. Time dependent CMV-STAT5A phosphorylation and 
determination of IFN-γ and TNF-α production. (A) PBMCs (3 * 106 cells/ml) were tested at 
different time points to determine the optimal time for pSTAT5 activation, (B, C) supernatants 
were collected and IFN-γ and TNF-α concentrations was determined by EIA at 24 hours, 
respectively. Each point represents the mean ± SD; *, p < 0.05, n = 3.  
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Supplementary Figure 4. CMV tetramer analysis of one HLA-A*02 positive/CMV negative 
donor (D1) and HLA-A*02 /CMV positive donors (D2, D3). HLA-A*02-restricted CMV 
peptide-HLA tetramers (VLEETSVML IE-1316-324 and NLVPMVATV pp65495-503) were 
multimerized with either Streptavidin BV421 or Streptavidin APC. PBMCs (5*106) were 
stained with CD45RA_FITC, CD8_PE, CD19_ECD, CCR7 PE-Cy7, CD3 Pacific Orange and 
BV421, APC multimers. CMV- specific CD8+ T cells were identified by gating double 
multimer staining on BV421 and APC for the same epitope (IE-1 (left panels), pp65 (right 
panels)). T cell antigen experience was determined by CCR7 and CD45RA staining. Negative 
and positive CMV T cells controls were run in parallel. The percentage of CMV specific 
CD8+ T cells are presented.  
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Intracellular protein phosphorylation is a critical step in cellular activation stimulated by the 
binding of various ligands to cell surface receptors. This process is initiated by activation of 
specific protein-tyrosine kinases associated with intracellular domains of the respective ligand 
receptor. JAK-STATs pathway is one of the main pathways in the cell activation process and 
given their important role in various PIDs, STATs proteins have been extensively studied in 
immune function in health and disease.  
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Therefore, our work has focused on investigating and evaluating STATs activation and 
establishing flow cytometric methods to assess their phosphorylation to be a surrogate marker 
as a fast and sensitive diagnostic tool to current methods such as WB.  
At the first, we studied STAT1 and STAT3 activation and established a flow cytometric 
procedure to analyze variations of INF-α- and IL-6-induced STAT1 and STAT3 
phosphorylation in T cells from whole blood, respectively (publication ΙΙ). To examine 
whether our results were specific, the samples were also analyzed by WB in parallel. After 
that, we validated the normal values of pSTAT1 and pSTAT3 based on 21 healthy adult 
controls according to an appropriate validation process. 
We showed that, in contrast to the conventional methods like WB, our assay offers a 
diagnostic benefit by avoiding labor and time consumption, with the advantage of achieving 
an earlier diagnosis, which potentially leads to improve treatment decisions; hence, patient’s 
outcome (publication ΙΙ).  
Furthermore, we verified FCM-based pSTAT1 and pSTAT3 profiling established here in 
patients group suffering from CMC and HIES. Our results demonstrated that pSTAT1 and 
pSTAT3 assay is an effective tool to identify and characterize well-known PIDs such as CMC 
and HIES, respectively (publication ΙΙ). 
Next, we introduced a fast and straightforward flow cytometric assay for the assessment of T 
cell proliferation, based on the staining of phosphorylated STAT5A (publication ΙΙΙ). We 
showed that pSTAT5A represents an appropriate approach to predict the behavior of T cells 
upon activation by CD3/CD28 and PHA. FCM-based pSTAT5A profiling is an intracellular 
flow cytometric method, enabling the early and reliable detection of T cell proliferation 
without long time incubation (within 24 h instead to 5 days). Importantly, measurement of 
pSTAT5A represents a new principle to assess T cell proliferation. It reveals important 
information on T cell biology by using series of kinetics and different kinds of T cell 
stimulation. For instance: [1] after stimulation via CD3/CD28 and negative pSTAT5A and T 
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cell proliferation, the immune defect could be occurred in the whole signaling cascade (TCR-
IL-2 transcription-JAK3-STAT5), [2] After stimulation via external IL-2 and negative 
pSTAT5A, the immune defect could be localized in the signaling cascade (IL-2R – JAK3 – 
STAT5), [3] After stimulation via external IL-2 and positive pSTAT5A, the immune defect 
could be localized in the signaling cascade (TCR - IL-2 transcription) (publication ΙΙΙ). 
We showed a strong correlation between the STAT5A phosphorylation and the percentage of 
dividing cells (publication ΙΙΙ). Later on, we used the measurement established here to 
investigate whether the phosphorylation of STAT5A is an appropriate candidate for 
predicting CMV specific T cell proliferation.  
 It is well-known that CMV specific T cells expand with CMV reactivation and are probably 
prerequisite for control and protection. We demonstrated that CMV specific pSTAT5A 
detection represents a fast and straightforward diagnostic tool to assess CMV specific T cell 
proliferation without requisite several days’ culture (publication ΙV).  
Furthermore, we showed a positive correlation between the percentage of pSTAT5A+ T cells 
vs. (1) CMV-IgG concentrations vs. (2) the percentage of expanded T cells and vs. (3) the 
percentage of initial CMV specific T cells (publication ΙV).   
Finally, we evaluated the diagnostic value of pSTAT5 assay and determined the percentage of 
pSTAT5A+ T cells cut-off value at which pSTAT5 assay has the greatest diagnostic potency.  
Our data showed that a cut-off value of 9.1 % could be used to assess CMV specific T cell 
proliferation with a specificity and sensitivity of 100% and 73%, respectively. 
We verified measurement established here by CMV specific T cells stimulation in three 
selected patients diagnosed with CARMIL2-mutation and suffering from chronic CMV  
infection. Our results showed that the complete and the partial deficiency of CMV and 
CD3/CD28 stimulated pSTAT5A correlated with the complete and the partial deficiency of 
CMV and CD3/CD28 stimulated T cell proliferation, respectively (publication ΙV).   
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In conclusion, disorders in JAKs-STATs signal pathways in T cells may result in insufficient 
response to stimulants. Therefore, FCM-based pSTATs profiling is an effective tool for 
clinical laboratory diagnostics [1] to understand the susceptibility to recurrent opportunistic 
infections [2] to rapidly identify T cell proliferation [3] to investigate tumor-specific 
responses of  CD8 T effector and memory cells (56) and finally [4] to identify and distinguish 
well-known PIDs like CARMIL-2 mutations, CMC, AD-HIES or AR-HIES. 
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